We describe a protective effect on autoimmune diabetes and a reduced destructive insulitis in NOD.scid recipients following splenocyte injections from diabetic NOD donors and sorted CD19+ cells compared to NOD.scid recipients receiving splenocytes alone. This protective effect was age-specific (only CD19+ cells from young NOD donors exerted this effect; p < 0.001). Furthermore, we found that CD19+IgM+ cells is the primary cell subpopulation of B cells that delayed adoptive transfer of diabetes mediated by diabetogenic T cells from NOD mice (p = 0.002). In fact, removal of IgM+ cells from the CD19+ pool did not result in diabetes protection. Blockade of IL-10 with neutralizing antibodies at the time of CD19+ cell co-transfers also abrogated the therapeutic effect, suggesting that IL-10 secretion was an important component of the protective effect. These results were strengthened by ex vivo incubation of CD19+ cells with IL-5, which resulted in enhanced IL-10 production and significantly delayed diabetes progression compared to controls (p = 0.0005). To the best of our knowledge, this is the first study demonstrating that CD19+IgM+ cells is the primary cell subpopulation of regulatory B cells delaying diabetes mediated by diabetogenic T cells from NOD mice. The potential to expand CD19+IgM+ cells, especially in response to increased stimulation using IL-5 or by pharmacologic agents, may be a new therapeutic option for type 1 diabetes.

Disclosure

A.D. Vonberg: None. M. Pietropaolo: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.